Publications by authors named "Robert Justice"

Claim this Profile
F
FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia.
R Angelo de Claro, Karen M McGinn, Nicole Verdun, Shwu-Luan Lee, Haw-Jyh Chiu, Robert Justice

Clin Cancer Res· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.
Sean Khozin, Gideon M Blumenthal, Lijun Zhang, Shenghui Tang, Margaret Brower, Robert Justice

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
Hyon-Zu Lee, Virginia E Kwitkowski, Pedro L Del Valle, M Stacey Ricci, Haleh Saber, Robert Justice

Clin Cancer Res· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of benefits and risks in development of targeted therapies for cancer--The view of regulatory authorities.
Francesco Pignatti, Bertil Jonsson, Gideon Blumenthal, Robert Justice

Mol Oncol· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma.
Barry W Miller, Donna Przepiorka, R Angelo de Claro, Kyung Lee, Lei Nie, Robert Justice

Clin Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease.
Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F Zirkelbach, Liang Zhao, Robert Justice

Clin Cancer Res· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
Laleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Robert Justice

Clin Cancer Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
Geoffrey Kim, Amy E McKee, Yang-Min Ning, Maitreyee Hazarika, Marc Theoret, Robert Justice

Clin Cancer Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.
Dickran Kazandjian, Gideon M Blumenthal, Huan-Yu Chen, Kun He, Mona Patel, Robert Justice

Oncologist· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer.
Laleh Amiri-Kordestani, Gideon M Blumenthal, Qiang Casey Xu, Lijun Zhang, Shenghui W Tang, Robert Justice

Clin Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and drug administration approval: obinutuzumab in combination with chlorambucil for the treatment of previously untreated chronic lymphocytic leukemia.
Hyon-Zu Lee, Barry W Miller, Virginia E Kwitkowski, Stacey Ricci, Pedro DelValle, Robert Justice

Clin Cancer Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.
Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P Costantino, Robert Justice

Lancet· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
Sean Khozin, Gideon M Blumenthal, Xiaoping Jiang, Kun He, Karen Boyd, Robert Justice

Oncologist· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Shakun M Malik, Virginia Ellen Maher, Karen E Bijwaard, Robert L Becker, Lijun Zhang, Robert Justice

Clin Cancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective.
Ethan Basch, Ann Marie Trentacosti, Laurie B Burke, Virginia Kwitkowski, Robert C Kane, Robert Justice

Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Letter to the Editor: Local Evaluation and Blinded Central Review Comparison a Victim of Meta-analysis Shortcomings.
Jenny J Zhang, Huanyu Chen, Kun He, Shenghui Tang, Robert Justice

Ther Innov Regul Sci· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary.
Paul G Kluetz, William Pierce, V Ellen Maher, Hui Zhang, Shenghui Tang, Robert Justice

Clin Cancer Res· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Paul G Kluetz, Yang-Min Ning, V Ellen Maher, Lijun Zhang, Shenghui Tang, Robert Justice

Clin Cancer Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary.
Yangmin M Ning, William Pierce, V Ellen Maher, Stella Karuri, Sheng-Hui Tang, Robert Justice

Clin Cancer Res· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Gideon M Blumenthal, Nancy S Scher, Patricia Cortazar, Somesh Chattopadhyay, Shenghui Tang, Robert Justice

Clin Cancer Res· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors.
Gideon M Blumenthal, Patricia Cortazar, Jenny J Zhang, Shenghui Tang, Rajeshwari Sridhara, Robert Justice

Oncologist· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Blinded Independent Central Review of Tumor Progression in Oncology Clinical Trials: A Meta-analysis.
Jenny J Zhang, Huanyu Chen, Kun He, Shenghui Tang, Robert Justice

Ther Innov Regul Sci· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
Martin H Cohen, John R Johnson, Robert Justice, Richard Pazdur

Oncologist· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.
Katherine Thornton, Geoffrey Kim, V Ellen Maher, Somesh Chattopadhyay, Shenghui Tang, Robert Justice

Clin Cancer Res· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
US Food and Drug Administration approval overview in metastatic breast cancer.
Patricia Cortazar, Robert Justice, John Johnson, Rajeshwari Sridhara, Patricia Keegan

J Clin Oncol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis